"Diphosphonates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic compounds which contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents.
| Descriptor ID |
D004164
|
| MeSH Number(s) |
D02.705.429.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Diphosphonates".
Below are MeSH descriptors whose meaning is more specific than "Diphosphonates".
This graph shows the total number of publications written about "Diphosphonates" by people in this website by year, and whether "Diphosphonates" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 1 | 1 | 2 |
| 2008 | 2 | 0 | 2 |
| 2009 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Diphosphonates" by people in Profiles.
-
Jategaonkar AA, Badhey AK, Sokoya M, Kadakia S, Mudrovich S, Ducic Y. Total mandibulectomy defect in the setting of chronic bisphosphonate use. Am J Otolaryngol. 2018 Sep - Oct; 39(5):649-651.
-
Qaseem A, Forciea MA, McLean RM, Denberg TD. Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians. Ann Intern Med. 2017 Jun 06; 166(11):818-839.
-
Banffy MB, Vrahas MS, Ready JE, Abraham JA. Nonoperative versus prophylactic treatment of bisphosphonate-associated femoral stress fractures. Clin Orthop Relat Res. 2011 Jul; 469(7):2028-34.
-
Derman R, Kohles JD, Babbitt A. Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment. Clin Interv Aging. 2009; 4:357-65.
-
Foster SA, Foley KA, Meadows ES, Johnston JA, Wang S, Pohl GM, Long SR. Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates. BMC Womens Health. 2008; 8:24.
-
King AE, Umland EM. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates. Pharmacotherapy. 2008 May; 28(5):667-77.
-
Zarowitz BJ, Stefanacci R, Hollenack K, O'Shea T. The application of evidence-based principles of care in older persons (issue 1): management of osteoporosis. J Am Med Dir Assoc. 2007 Mar; 8(3 Suppl 2):e51-7.
-
Morris GJ, Mitchell EP. Bisphosphonate therapy for women with breast cancer and at high risk for osteoporosis. J Natl Med Assoc. 2007 Jan; 99(1):35-45.
-
Pullman-Mooar S, Mooar P. Osteoporosis treatment after hip fracture: slow progress. J Clin Rheumatol. 2005 Apr; 11(2):65-7.
-
Kelly WK, Steineck G. Bisphosphonates for men with prostate cancer: sifting through the rubble. J Clin Oncol. 2003 Dec 1; 21(23):4261-2.